Clinical Trials Logo

Nonalcoholic Steatohepatitis clinical trials

View clinical trials related to Nonalcoholic Steatohepatitis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04216693 Withdrawn - Clinical trials for Nonalcoholic Steatohepatitis

Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH)

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess if digoxin is safe and efficacious in treating patients with non-alcoholic steatohepatitis (NASH) within the approved target range of 0.7 to 1 ng/ml.

NCT ID: NCT03163810 Withdrawn - Clinical trials for Nonalcoholic Steatohepatitis

A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH)

Start date: February 6, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether low level laser therapy (LLLT) using the Erchonia VERJU and EVRL laser devices is effective in reducing aminoalanine transaminase (ALT) levels in individuals with nonalcoholic steatohepatitis (NASH).

NCT ID: NCT02769091 Withdrawn - Clinical trials for Type 2 Diabetes Mellitus

A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes

NASH
Start date: September 30, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effect of TEV-45478, as compared with placebo, on liver health and liver fat content in patients with T2DM who also have Nonalcoholic Steatohepatitis (NASH).

NCT ID: NCT01466894 Withdrawn - Clinical trials for Nonalcoholic Steatohepatitis

Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis

Start date: December 2012
Phase: Phase 2
Study type: Interventional

This is a multi-center, randomized, placebo-controlled, double-blind, dose-selection, multiple dose administration study comprising three groups, with up to 40 patients in each active treatment and placebo group. Patients with biopsy proven nonalcoholic steatohepatitis (NASH) and elevated liver enzymes will be randomized to undergo a liver MRI scan and to receive Imm 124-E or placebo for 24 weeks. During this period, patients will be followed for clinical and laboratory effects. At the end of 24 weeks of treatment, patients will undergo a second liver MRI scan. Patients will be followed for an additional 4 weeks for safety after completion of treatment.